WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, August 28, 2007

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,EPAB; PLUR=YES; OP=ADJ		
☐	L32	L31 and L25	0
☐	L31	L28.ab.	24
☐	L30	L29 and L1	240
☐	L29	L28 and L25	258
☐	L28	acetazolamide	2749
☐	L27	acetazolamide.pn.	0
☐	L26	L25 and L2	0
☐	L25	(positron emission tomography)	8204
☐	L24	L23 and L21	1
☐	L23	(positron emission tomography) or PET	119840
☐	L22	L21 AND (inhibitor or antagonist)	1
☐	L21	6027887.PN.	1
☐	L20	L19 and hypoxi$	0
☐	L19	L18 and L10	1
☐	L18	L17 and fluorescein	1
☐	L17	6027887.pn.	1
☐	L16	L15 and sulfonam$	7
☐	L15	L6 not @ay>2002	13
☐	L14	(antibod$ same inhibit) and L7	5
☐	L13	L10 and inhibit$	6
☐	L12	antibod$ and L4	3
☐	L11	antibod$ an dl4	0
☐	L10	L9 and L1	6
☐	L9	L8 not @ay>2002	6
☐	L8	L7 and antibod$	13
☐	L7	L6 and (antagon$ or inhibitor)	23
☐	L6	L5 and L3	31
☐	L5	tumor$ or cancer$ or neoplas$	228669
☐	L4	supuran.in.	4
☐	L3	L2 and (diagnos$ or determin$)	103
☐	L2	L1.ab.	243

☐	L1	carbonic anhydrase	6346

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAY 01	New CAS web site launched
NEWS 3	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 7	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 8	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 9	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 10	JUN 29	STN Viewer now available
NEWS 11	JUN 29	STN Express, Version 8.2, now available
NEWS 12	JUL 02	LEMBASE coverage updated
NEWS 13	JUL 02	LMEDLINE coverage updated
NEWS 14	JUL 02	SCISEARCH enhanced with complete author names
NEWS 15	JUL 02	CHEMCATS accession numbers revised
NEWS 16	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 17	JUL 16	CAplus enhanced with French and German abstracts
NEWS 18	JUL 18	CA/CAplus patent coverage enhanced
NEWS 19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20	JUL 30	USGENE now available on STN
NEWS 21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 22	AUG 06	BEILSTEIN updated with new compounds
NEWS 23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 24	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 25	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 26	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 27	AUG 27	USPATOLD now available on STN
NEWS 28	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:53:57 ON 28 AUG 2007

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 07:54:12 ON 28 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Aug 2007 VOL 147 ISS 10
FILE LAST UPDATED: 27 Aug 2007 (20070827/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s us 20040146955/pn
L1 1 US 20040146955/PN
(US2004146955/PN)

=> sel rn
E1 THROUGH E108 ASSIGNED

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.56	2.77

FILE 'REGISTRY' ENTERED AT 07:54:29 ON 28 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 AUG 2007 HIGHEST RN 945649-99-0
DICTIONARY FILE UPDATES: 27 AUG 2007 HIGHEST RN 945649-99-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> s e1-e108
             1 138-39-6/BI
               (138-39-6/RN)
             1 3523-95-3/BI
               (3523-95-3/RN)
             1 35303-76-5/BI
               (35303-76-5/RN)
             1 63-74-1/BI
               (63-74-1/RN)
             1 120-97-8/BI
               (120-97-8/RN)
             1 120279-96-1/BI
               (120279-96-1/RN)
             1 121-30-2/BI
               (121-30-2/RN)
             1 138-41-0/BI
               (138-41-0/RN)
             1 138890-62-7/BI
               (138890-62-7/RN)
             1 14949-00-9/BI
               (14949-00-9/RN)
             1 165668-41-7/BI
               (165668-41-7/RN)
             1 2153-13-1/BI
               (2153-13-1/RN)
             1 215998-40-6/BI
               (215998-40-6/RN)
             1 215998-42-8/BI
               (215998-42-8/RN)
             1 215998-44-0/BI
               (215998-44-0/RN)
             1 215998-46-2/BI
               (215998-46-2/RN)
             1 215998-48-4/BI
               (215998-48-4/RN)
             1 215998-50-8/BI
               (215998-50-8/RN)
             1 215998-52-0/BI
               (215998-52-0/RN)
             1 215998-54-2/BI
               (215998-54-2/RN)
             1 215998-56-4/BI
               (215998-56-4/RN)
             1 215998-58-6/BI
               (215998-58-6/RN)
             1 215998-60-0/BI
               (215998-60-0/RN)
             1 215998-62-2/BI
               (215998-62-2/RN)
             1 215998-64-4/BI
               (215998-64-4/RN)
             1 215998-66-6/BI
               (215998-66-6/RN)
             1 215998-68-8/BI
```

(215998-68-8/RN)
1 215998-70-2/BI
(215998-70-2/RN)
1 215998-72-4/BI
(215998-72-4/RN)
1 215998-74-6/BI
(215998-74-6/RN)
1 215998-76-8/BI
(215998-76-8/RN)
1 215998-78-0/BI
(215998-78-0/RN)
1 215998-80-4/BI
(215998-80-4/RN)
1 215998-82-6/BI
(215998-82-6/RN)
1 215998-84-8/BI
(215998-84-8/RN)
1 215998-86-0/BI
(215998-86-0/RN)
1 215998-88-2/BI
(215998-88-2/RN)
1 215998-90-6/BI
(215998-90-6/RN)
1 215998-92-8/BI
(215998-92-8/RN)
1 215998-94-0/BI
(215998-94-0/RN)
1 215998-96-2/BI
(215998-96-2/RN)
1 215998-98-4/BI
(215998-98-4/RN)
1 215999-00-1/BI
(215999-00-1/RN)
1 215999-02-3/BI
(215999-02-3/RN)
1 215999-04-5/BI
(215999-04-5/RN)
1 215999-06-7/BI
(215999-06-7/RN)
1 215999-08-9/BI
(215999-08-9/RN)
1 215999-10-3/BI
(215999-10-3/RN)
1 215999-12-5/BI
(215999-12-5/RN)
1 215999-14-7/BI
(215999-14-7/RN)
1 215999-16-9/BI
(215999-16-9/RN)
1 215999-18-1/BI
(215999-18-1/RN)
1 216885-10-8/BI
(216885-10-8/RN)
1 2368-84-5/BI
(2368-84-5/RN)
1 244122-00-7/BI
(244122-00-7/RN)
1 259131-75-4/BI
(259131-75-4/RN)
1 29927-14-8/BI
(29927-14-8/RN)
1 3306-62-5/BI
(3306-62-5/RN)
1 345970-47-0/BI

(345970-47-0/RN)
1 345970-48-1/BI
(345970-48-1/RN)
1 35203-91-9/BI
(35203-91-9/RN)
1 4392-54-5/BI
(4392-54-5/RN)
1 452-35-7/BI
(452-35-7/RN)
1 53297-68-0/BI
(53297-68-0/RN)
1 53297-69-1/BI
(53297-69-1/RN)
1 547-52-4/BI
(547-52-4/RN)
1 554-57-4/BI
(554-57-4/RN)
1 59-66-5/BI
(59-66-5/RN)
1 60154-06-5/BI
(60154-06-5/RN)
1 606-25-7/BI
(606-25-7/RN)
1 654-62-6/BI
(654-62-6/RN)
1 67472-44-0/BI
(67472-44-0/RN)
1 688805-64-3/BI
(688805-64-3/RN)
1 688805-66-5/BI
(688805-66-5/RN)
1 688805-68-7/BI
(688805-68-7/RN)
1 688805-70-1/BI
(688805-70-1/RN)
1 688805-72-3/BI
(688805-72-3/RN)
1 688805-74-5/BI
(688805-74-5/RN)
1 688805-76-7/BI
(688805-76-7/RN)
1 688805-78-9/BI
(688805-78-9/RN)
1 688805-80-3/BI
(688805-80-3/RN)
1 688805-82-5/BI
(688805-82-5/RN)
1 688805-84-7/BI
(688805-84-7/RN)
1 688805-86-9/BI
(688805-86-9/RN)
1 688805-87-0/BI
(688805-87-0/RN)
1 688805-89-2/BI
(688805-89-2/RN)
1 688805-91-6/BI
(688805-91-6/RN)
1 688805-93-8/BI
(688805-93-8/RN)
1 688805-97-2/BI
(688805-97-2/RN)
1 688805-99-4/BI
(688805-99-4/RN)
1 688806-01-1/BI

(688806-01-1/RN)
1 700378-86-5/BI
(700378-86-5/RN)
1 78160-85-7/BI
(78160-85-7/RN)
1 78160-87-9/BI
(78160-87-9/RN)
1 79783-03-2/BI
(79783-03-2/RN)
1 829-71-0/BI
(829-71-0/RN)
1 83439-56-9/BI
(83439-56-9/RN)
1 86029-46-1/BI
(86029-46-1/RN)
1 878502-00-2/BI
(878502-00-2/RN)
1 878502-01-3/BI
(878502-01-3/RN)
1 878502-02-4/BI
(878502-02-4/RN)
1 878502-03-5/BI
(878502-03-5/RN)
1 878502-04-6/BI
(878502-04-6/RN)
1 878502-05-7/BI
(878502-05-7/RN)
1 878502-06-8/BI
(878502-06-8/RN)
1 88615-09-2/BI
(88615-09-2/RN)
1 9001-03-0/BI
(9001-03-0/RN)
1 98-18-0/BI
(98-18-0/RN)

L2 108 (138-39-6/BI OR 3523-95-3/BI OR 35303-76-5/BI OR 63-74-1/BI OR 120-97-8/BI OR 120279-96-1/BI OR 121-30-2/BI OR 138-41-0/BI OR 138890-62-7/BI OR 14949-00-9/BI OR 165668-41-7/BI OR 2153-13-1/BI OR 215998-40-6/BI OR 215998-42-8/BI OR 215998-44-0/BI OR 215998-46-2/BI OR 215998-48-4/BI OR 215998-50-8/BI OR 215998-52-0/BI OR 215998-54-2/BI OR 215998-56-4/BI OR 215998-58-6/BI OR 215998-60-0/BI OR 215998-62-2/BI OR 215998-64-4/BI OR 215998-66-6/BI OR 215998-68-8/BI OR 215998-70-2/BI OR 215998-72-4/BI OR 215998-74-6/BI OR 215998-76-8/BI OR 215998-78-0/BI OR 215998-80-4/BI OR 215998-82-6/BI OR 215998-84-8/BI OR 215998-86-0/BI OR 215998-88-2/BI OR 215998-90-6/BI OR 215998-92-8/BI OR 215998-94-0/BI OR 215998-96-2/BI OR 215998-98-4/BI OR 215999-00-1/BI OR 215999-02-3/BI OR 215999-04-5/BI OR 215999-06-7/BI OR 215999-08-9/BI OR 215999-10-3/BI OR 215999-12-5/BI OR 215999-14-7/BI OR 215999-16-9/BI OR 215999-18-1/BI OR 216885-10-8/BI OR 2368-84-5/BI OR 244122-00-7/BI OR 259131-75-4/BI OR 2992

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	3.22

FILE 'CAPLUS' ENTERED AT 07:54:49 ON 28 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Aug 2007 VOL 147 ISS 10
FILE LAST UPDATED: 27 Aug 2007 (20070827/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> d his

     (FILE 'HOME' ENTERED AT 07:53:57 ON 28 AUG 2007)

     FILE 'CAPLUS' ENTERED AT 07:54:12 ON 28 AUG 2007
L1             1 S US 20040146955/PN
                 SEL RN

     FILE 'REGISTRY' ENTERED AT 07:54:29 ON 28 AUG 2007
L2           108 S E1-E108

     FILE 'CAPLUS' ENTERED AT 07:54:49 ON 28 AUG 2007

=> s l2
L3         23381 L2

=> s l2/biol
           23381 L2
         7024327 BIOL/RL
L4         10414 L2/BIOL
                   (L2 (L) BIOL/RL)

=> s cancer? or tumor? or neoplas?
          343513 CANCER?
          481852 TUMOR?
          507305 NEOPLAS?
L5        799250 CANCER? OR TUMOR? OR NEOPLAS?

=> s l4 and l5
L6           909 L4 AND L5

=> s diag?
L7        553334 DIAG?

=> s l7 (L) l5
L8         57089 L7 (L) L5

=> s l8 and l4
L9           181 L8 AND L4

=> s l9 not py>2002
         5672540 PY>2002
L10           23 L9 NOT PY>2002

=> d ibib 1-10

L10  ANSWER 1 OF 23  CAPLUS  COPYRIGHT 2007 ACS on STN
```

ACCESSION NUMBER: 2002:942244 CAPLUS
DOCUMENT NUMBER: 138:151256
TITLE: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer
AUTHOR(S): Kaanders, Johannes H. A. M.; Wijffels, Karien I. E. M.; Marres, Henri A. M.; Ljungkvist, Anna S. E.; Pop, Lucas A. M.; Van den Hoogen, Franciscus J. A.; De Wilde, Peter C. M.; Bussink, Johan; Raleigh, James A.; Van der Kogel, Albert J.
CORPORATE SOURCE: Department of Radiation Oncology, University Medical Center Nijmegen, Nijmegen, 6500 HB, Neth.
SOURCE: Cancer Research (2002), 62(23), 7066-7074
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:579681 CAPLUS
DOCUMENT NUMBER: 138:167618
TITLE: Differential gene expression in renal-cell cancer
AUTHOR(S): Skubitz, Keith M.; Skubitz, Amy P. N.
CORPORATE SOURCE: Departments of Medicine and Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN, USA
SOURCE: Journal of Laboratory and Clinical Medicine (2002), 140(1), 52-64
CODEN: JLCMAK; ISSN: 0022-2143
PUBLISHER: Mosby, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:510395 CAPLUS
DOCUMENT NUMBER: 138:104572
TITLE: Molecular determinants of human uveal melanoma invasion and metastasis
AUTHOR(S): Seftor, Elisabeth A.; Meltzer, Paul S.; Kirschmann, Dawn A.; Pe'er, Jacob; Maniotis, Andrew J.; Trent, Jeffrey M.; Folberg, Robert; Hendrix, Mary J. C.
CORPORATE SOURCE: Department of Anatomy and Cell Biology, College of Medicine and The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA
SOURCE: Clinical & Experimental Metastasis (2002), 19(3), 233-246
CODEN: CEXMD2; ISSN: 0262-0898
PUBLISHER: Kluwer Academic Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:506032 CAPLUS
DOCUMENT NUMBER: 137:199256
TITLE: HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron
AUTHOR(S): Mandriota, Stefano J.; Turner, Kevin J.; Davies, David R.; Murray, Paul G.; Morgan, Neil V.; Sowter, Heidi

M.; Wykoff, Charles C.; Maher, Eamonn R.; Harris, Adrian L.; Ratcliffe, Peter J.; Maxwell, Patrick H.
CORPORATE SOURCE: Wellcome Trust Centre for Human Genetics, Oxford, OX3 7BN, UK
SOURCE: Cancer Cell (2002), 1(5), 459-468
CODEN: CCAECI; ISSN: 1535-6108
PUBLISHER: Cell Press
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:743200 CAPLUS
DOCUMENT NUMBER: 136:35588
TITLE: Secreted and cell surface genes expressed in benign and malignant colorectal tumors
AUTHOR(S): Buckhaults, Phillip; Rago, Carlo; St. Croix, Brad; Romans, Katharine E.; Saha, Saurabh; Zhang, Lin; Vogelstein, Bert; Kinzler, Kenneth W.
CORPORATE SOURCE: Howard Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA
SOURCE: Cancer Research (2001), 61(19), 6996-7001
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:584391 CAPLUS
DOCUMENT NUMBER: 135:286595
TITLE: Genetic analysis of early- versus late-stage ovarian tumors
AUTHOR(S): Shridhar, Viji; Lee, John; Pandita, Ajay; Iturria, Steve; Avula, Rajeswari; Staub, Julie; Morrissey, Mike; Calhoun, Eric; Sen, Ami; Kalli, Kimberly; Keeney, Gary; Roche, Patrick; Cliby, William; Lu, Karen; Schmandt, Rosemarie; Mills, Gordon B.; Bast, Robert C., Jr.; James, C. David; Couch, Fergus J.; Hartmann, Lynn C.; Lillie, Jim; Smith, David I.
CORPORATE SOURCE: Departments of Experimental Pathology, Division of Laboratory Medicine, The Mayo Clinic, Rochester, MN, 55905, USA
SOURCE: Cancer Research (2001), 61(15), 5895-5904
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:361504 CAPLUS
DOCUMENT NUMBER: 135:146678
TITLE: Carbonic anhydrase inhibitors
AUTHOR(S): Supuran, Claudiu T.; Scozzafava, Andrea
CORPORATE SOURCE: Universita degli Studi, Laboratorio di Chimica Inorganica e Bioinorganica, Florence, I-50121, Italy
SOURCE: Current Medicinal Chemistry: Immunology, Endocrine & Metabolic Agents (2001), 1(1), 61-97
CODEN: CMCIC8; ISSN: 1568-0134
PUBLISHER: Bentham Science Publishers Ltd.

DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 152 THERE ARE 152 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:320060 CAPLUS
DOCUMENT NUMBER: 134:339179
TITLE: Nucleic acids and proteins associated with cancer as antitumor targets
INVENTOR(S): Burmer, Glenna C.; Brown, Joseph P.; Pritchard, David
PATENT ASSIGNEE(S): Lifespan Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030964	A2	20010503	WO 2000-US29126	20001020
WO 2001030964	A3	20010809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001013397	A	20010508	AU 2001-13397	20001020
PRIORITY APPLN. INFO.:			US 1999-161232P P	19991022
			US 2000-693783 A	20001019
			WO 2000-US29126 W	20001020

L10 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:247374 CAPLUS
DOCUMENT NUMBER: 134:276523
TITLE: Hypoxia-related human genes and their encoded proteins and diagnostic and therapeutic uses
INVENTOR(S): Denko, Nicholas C.; Giaccia, Amato J.; Green, Christopher J.; Laderoute, Keith R.; Schindler, Cornelia; Koong, Albert Ching-Wei
PATENT ASSIGNEE(S): Varian Associates, Inc., USA
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023426	A2	20010405	WO 2000-US27189	20001002
WO 2001023426	A3	20011101		
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,				

```
            MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
            CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                      US 1999-410375      A  19990930

L10  ANSWER 10 OF 23  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2000:748205  CAPLUS
DOCUMENT NUMBER:         133:361435
TITLE:                   Expression of transmembrane carbonic anhydrase
                         isoenzymes IX and XII in normal human pancreas and
                         pancreatic tumors
AUTHOR(S):               Kivela, Antti J.; Parkkila, Seppo; Saarnio, Juha;
                         Karttunen, Tuomo J.; Kivela, Jyrki; Parkkila,
                         Anna-Kaisa; Pastorekova, Silvia; Pastorek, Jaromir;
                         Waheed, Abdul; Sly, William S.; Rajaniemi, Hannu
CORPORATE SOURCE:        Department of Anatomy and Cell Biology, University of
                         Oulu, Oulu, 90014, Finland
SOURCE:                  Histochemistry and Cell Biology (2000), 114(3),
                         197-204
                         CODEN: HCBIFP; ISSN: 0948-6143
PUBLISHER:               Springer-Verlag
DOCUMENT TYPE:           Journal
LANGUAGE:                English
REFERENCE COUNT:         27    THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 07:53:57 ON 28 AUG 2007)

     FILE 'CAPLUS' ENTERED AT 07:54:12 ON 28 AUG 2007
L1             1 S US 20040146955/PN
                 SEL RN

     FILE 'REGISTRY' ENTERED AT 07:54:29 ON 28 AUG 2007
L2           108 S E1-E108

     FILE 'CAPLUS' ENTERED AT 07:54:49 ON 28 AUG 2007
L3         23381 S L2
L4         10414 S L2/BIOL
L5        799250 S CANCER? OR TUMOR? OR NEOPLAS?
L6           909 S L4 AND L5
L7        553334 S DIAG?
L8         57089 S L7 (L) L5
L9           181 S L8 AND L4
L10           23 S L9 NOT PY>2002

=> s l10 and inhibit?
       1955429 INHIBIT?
L11            9 L10 AND INHIBIT?

=> d ibib ab 1-9

L11  ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2002:510395  CAPLUS
DOCUMENT NUMBER:         138:104572
TITLE:                   Molecular determinants of human uveal melanoma
                         invasion and metastasis
AUTHOR(S):               Seftor, Elisabeth A.; Meltzer, Paul S.; Kirschmann,
                         Dawn A.; Pe'er, Jacob; Maniotis, Andrew J.; Trent,
                         Jeffrey M.; Folberg, Robert; Hendrix, Mary J. C.
CORPORATE SOURCE:        Department of Anatomy and Cell Biology, College of
```

Medicine and The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA

SOURCE: Clinical & Experimental Metastasis (2002), 19(3), 233-246
CODEN: CEXMD2; ISSN: 0262-0898

PUBLISHER: Kluwer Academic Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The mol. anal. of cancer has benefited tremendously from the sequencing of the human genome integrated with the science of bioinformatics. Microarray anal. technol. has the potential to classify tumors based on the differential expression of genes. In the current study, a collaborative, multidisciplinary approach was utilized to study the mol. determinants of human uveal melanoma invasion and metastasis. Uveal melanoma is considered the most common primary intraocular cancer in adults, resulting in the death of approx. 50% of patients affected. Unfortunately, at the time of diagnosis , many patients already harbor microscopic metastases, thus underscoring a critical need to identify prognostic markers indicative of metastatic potential. The investigative strategy consisted of isolating highly invasive vs. poorly invasive uveal melanoma cells from a heterogeneous tumor derived from cells that had metastasized from the eye to the liver. The heterogeneous tissue explant MUM-2 led to the derivation of two clonal cell lines: MUM-2B and MUM-2C. Further morphol. and functional analyses revealed that the MUM-2B cells were epithelioid, interconverted (expressing mesenchymal and epithelial phenotypes) highly invasive, and demonstrated vasculogenic mimicry. The MUM-2C cells were spindle-like, expressed only a vimentin mesenchymal phenotype, poorly invasive, and were incapable of vasculogenic mimicry. The mol. anal. of the MUM-2B vs. the MUM-2C clones resulted in the differential expression of 210 known genes. Overall, the mol. signature of the MUM-2B cells resembled that of multiple phenotypes - similar to a pluripotent, embryonic-like genotype. Validation of select genes that were upregulated and down-regulated was conducted by semiquant. RT-PCR measurement. This study provides a mol. profile that will hopefully lead to the development of new mol. targets for therapeutic intervention and possible diagnostic markers to predict the clin. outcome of patients with uveal melanoma.

REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:743200 CAPLUS
DOCUMENT NUMBER: 136:35588
TITLE: Secreted and cell surface genes expressed in benign and malignant colorectal tumors
AUTHOR(S): Buckhaults, Phillip; Rago, Carlo; St. Croix, Brad; Romans, Katharine E.; Saha, Saurabh; Zhang, Lin; Vogelstein, Bert; Kinzler, Kenneth W.
CORPORATE SOURCE: Howard Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA
SOURCE: Cancer Research (2001), 61(19), 6996-7001
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Serial anal. of gene expression was used to identify transcripts encoding secreted or cell surface proteins that were expressed in benign and malignant tumors of the colorectum. A total of 290,394 tags were analyzed from normal, adenomatous, and cancerous colonic epithelium. Of the 21,343 different transcripts observed, 957 were found to be differentially expressed between normal tissue and adenoma or between normal tissue and cancer. Forty-nine transcripts were elevated ≥20-fold in adenomas, 40 transcripts were elevated ≥20-fold in cancers, and 9 transcripts were elevated ≥20-fold in

both. Products of six of these nine transcripts (TGFBI, LYS, RDP, MIC-1, REGA, and DEHL) were predicted to be secreted or to reside on the cell surface, and these were analyzed in more detail. The abnormal expression levels predicted by serial anal. of gene expression were confirmed by quant. PCR analyses of each of these six genes. Moreover, the cell types responsible for the elevated expression were identified by in situ hybridization and by PCR analyses of epithelial cells immunoaffinity purified from primary tumors. This study extends knowledge of the differences in gene expression that underlie various stages of neoplasia and suggests specific diagnostic approaches that may be useful for the early detection of colorectal neoplasia .

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:361504 CAPLUS
DOCUMENT NUMBER: 135:146678
TITLE: Carbonic anhydrase inhibitors
AUTHOR(S): Supuran, Claudiu T.; Scozzafava, Andrea
CORPORATE SOURCE: Universita degli Studi, Laboratorio di Chimica Inorganica e Bioinorganica, Florence, I-50121, Italy
SOURCE: Current Medicinal Chemistry: Immunology, Endocrine & Metabolic Agents (2001), 1(1), 61-97
CODEN: CMCIC8; ISSN: 1568-0134
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 151 refs. CAs (EC 4.2.1.1) are wide-spread zinc enzymes, present in mammals in at least 14 different isoforms. Some of these isoenzymes are cytosolic (CA I, CA II, CA III, CA VII), others are membrane-bound (CA IV, CA IX, CA XII and CA XIV), CA V is mitochondrial and CA VI is secreted in the saliva. Three acatalytic forms are also known (CARP VIII, CARP X and CARP XI). Several important physiol. and physio-pathol. functions are played by many CA isoenzymes, which are strongly inhibited by aromatic and heterocyclic sulfonamides. The catalytic and inhibition mechanisms of these enzymes are understood in great detail, and this greatly helped the design of potent inhibitors, some of which possess important clin. applications. The use of such enzyme inhibitors as antiglaucoma drugs will be discussed in detail, together with the recent developments that led to isoenzyme-specific and organ-selective inhibitors. A recent discovery is connected with the involvement of CAs and their sulfonamide inhibitors in cancer: several potent sulfonamide inhibitors inhibited the growth of a multitude of tumor cells in vitro and in vivo, constituting thus interesting leads for developing novel antitumor therapies. Furthermore, some other classes of compds. that interact with CAs have recently been discovered, some of which possess modified sulfonamide or hydroxamate moieties. Some sulfonamides have also applications as diagnostic tools, in PET and MRI. Future prospects for drug design applications for inhibitors of these ubiquitous enzymes will also be discussed.
REFERENCE COUNT: 152 THERE ARE 152 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:320060 CAPLUS
DOCUMENT NUMBER: 134:339179
TITLE: Nucleic acids and proteins associated with cancer as antitumor targets
INVENTOR(S): Burmer, Glenna C.; Brown, Joseph P.; Pritchard, David
PATENT ASSIGNEE(S): Lifespan Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030964	A2	20010503	WO 2000-US29126	20001020
WO 2001030964	A3	20010809		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001013397	A	20010508	AU 2001-13397	20001020
PRIORITY APPLN. INFO.:			US 1999-161232P	P 19991022
			US 2000-693783	A 20001019
			WO 2000-US29126	W 20001020

AB This invention relates to the discovery of nucleic acids associated with cell proliferation, neoplasia, cell transformation, malignant tumor formation and metastasis and uses therefor. The present invention provides a method for cancer diagnosing by detecting the overexpression or the underexpression of a cancer -associated mRNA in the tissue of interest, preferably in liver, breast, prostate, kidney and colon. In another aspect, the invention provides methods for arresting cancer and a method for identifying a modulators of cancer development.

L11 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:247374 CAPLUS
DOCUMENT NUMBER: 134:276523
TITLE: Hypoxia-related human genes and their encoded proteins and diagnostic and therapeutic uses
INVENTOR(S): Denko, Nicholas C.; Giaccia, Amato J.; Green, Christopher J.; Laderoute, Keith R.; Schindler, Cornelia; Koong, Albert Ching-Wei
PATENT ASSIGNEE(S): Varian Associates, Inc., USA
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023426	A2	20010405	WO 2000-US27189	20001002
WO 2001023426	A3	20011101		

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:			US 1999-410375	A 19990930

AB The polynucleotide and polypeptide sequences of two novel hypoxia-inducible human and murine genes, HIG1 and HIG2, are described. In addition, a number of known genes and ESTs are established as being hypoxia-inducible and hypoxia-repressible. Polynucleotide and polypeptide arrays comprising the hypoxia-inducible and hypoxia-repressible gene sequences, proteins, or antibodies which specifically bind the proteins are disclosed. Methods for using the hypoxia-inducible and hypoxia-repressible gene sequences and proteins, and arrays thereof, to diagnose and treat hypoxia-related conditions such as cancer and ischemia are also provided.

L11 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:262841 CAPLUS
DOCUMENT NUMBER: 124:314359
TITLE: A marker antigen for non-small cell lung cancer and a cDNA encoding it and their uses
INVENTOR(S): Torczynski, Richard M.; Bollon, Arthur P.
PATENT ASSIGNEE(S): Cytoclonal Pharmaceutics, Inc., USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9602552	A1	19960201	WO 1995-US9145	19950719
W: AU, BR, CA, CN, FI, JP, KE, KR, LK, MN, MX, NO, NZ, PL, RU, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5589579	A	19961231	US 1994-276919	19940719
CA 2195403	A1	19960201	CA 1995-2195403	19950719
AU 9533592	A	19960216	AU 1995-33592	19950719
AU 700915	B2	19990114		
EP 804451	A1	19971105	EP 1995-930093	19950719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
BR 9508417	A	19971118	BR 1995-8417	19950719
JP 10503087	T	19980324	JP 1995-505257	19950719
US 5773579	A	19980630	US 1997-776088	19970121
PRIORITY APPLN. INFO.:			US 1994-276919 A	19940719
			WO 1995-US9145 W	19950719

AB A cDNA and the corresponding protein for a novel protein specific for human lung cancer cells are described. This gene is expressed at a much higher level in these cells than in normal lung cells, other normal tissues and other tumor cell lines tested. Genes for forms of the protein lacking a membrane spanning region and with amino acid substitutions affecting a potential phosphorylation site are also described. Nucleic acid probes for the detection of lung cancer cells from tissue biopsy and body fluids such as serum sputum and bronchial washings are derived from the gene. Manufacture of the antigen in a host cell and its use as an immunogen in antibody production for test applications is described. An ELISA test to measure shed antigen present in patient samples as well as an enzyme test to measure activity in specimens are also described. The protein has features common to human carbonic anhydrases and is named HCAVIII (human carbonic anhydrase VIII).

L11 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:881452 CAPLUS
DOCUMENT NUMBER: 123:296614
TITLE: Pretargeting methods and compounds with reduced immunogenicity of targeting moiety-anti-ligand conjugates or other components employed in diagnostic and therapeutic pretargeting protocols
INVENTOR(S): Graves, Scott S.; Bjorn, Michael J.; Reno, John M.;

Axworthy, Donald B.; Fritzberg, Alan R.; Theodore, Louis J.
PATENT ASSIGNEE(S): Neorx Corp., USA
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9515770	A1	19950615	WO 1994-US14223	19941209
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1993-164302 A 19931209

AB Methods, compds., compns., and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods and agents are provided for reducing the immunogenicity of targeting moiety-anti-ligand conjugates or other components employed in diagnostic and therapeutic pretargeting protocols. Preparation of various conjugates for use in the invention is included. Examples include e.g. in vivo anal. of a radiolabeled chelate-biotin conjugate administered after antibody pretargeting, clearing agent evaluation, two- and three-step pretargeting methodol., administration of a monoclonal antibody (MAb)-streptavidin conjugate in humans, and immunosuppression of MAb-containing conjugates.

L11 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:429021 CAPLUS
DOCUMENT NUMBER: 122:179383
TITLE: Identification of ligands by selective amplification of cells transfected with receptors
INVENTOR(S): Brann, Mark Robert
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9502823	A1	19950126	WO 1994-US7900	19940713
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SE, SK, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
IL 110298	A	19990411	IL 1994-110298	19940712
CA 2167048	A1	19950126	CA 1994-2167048	19940713
CA 2167048	C	20010925		
AU 9473330	A	19950213	AU 1994-73330	19940713
AU 679253	B2	19970626		
EP 708922	A1	19960501	EP 1994-923478	19940713
EP 708922	B1	19990310		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09500023	T	19970107	JP 1995-504713	19940713
JP 3102571	B2	20001023		
AT 177535	T	19990315	AT 1994-923478	19940713
ES 2129658	T3	19990616	ES 1994-923478	19940713

PRIORITY APPLN. INFO.: US 1993-91694 A 19930713
WO 1994-US7900 W 19940713

AB A method of detecting a substance capable of acting as a ligand comprises (a) incubating, under conditions permitting cell amplification, cells transfected with DNA coding for a receptor capable of influencing cell

Inorganica e Bioinorganica, Florence, I-50121, Italy
SOURCE: Current Medicinal Chemistry: Immunology, Endocrine & Metabolic Agents (2001), 1(1), 61-97
CODEN: CMCIC8; ISSN: 1568-0134
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 151 refs. CAs (EC 4.2.1.1) are wide-spread zinc enzymes, present in mammals in at least 14 different isoforms. Some of these isoenzymes are cytosolic (CA I, CA II, CA III, CA VII), others are membrane-bound (CA IV, CA IX, CA XII and CA XIV), CA V is mitochondrial and CA VI is secreted in the saliva. Three acatalytic forms are also known (CARP VIII, CARP X and CARP XI). Several important physiol. and physio-pathol. functions are played by many CA isoenzymes, which are strongly inhibited by aromatic and heterocyclic sulfonamides. The catalytic and inhibition mechanisms of these enzymes are understood in great detail, and this greatly helped the design of potent inhibitors, some of which possess important clin. applications. The use of such enzyme inhibitors as antiglaucoma drugs will be discussed in detail, together with the recent developments that led to isoenzyme-specific and organ-selective inhibitors. A recent discovery is connected with the involvement of CAs and their sulfonamide inhibitors in cancer: several potent sulfonamide inhibitors inhibited the growth of a multitude of tumor cells in vitro and in vivo, constituting thus interesting leads for developing novel antitumor therapies. Furthermore, some other classes of compds. that interact with CAs have recently been discovered, some of which possess modified sulfonamide or hydroxamate moieties. Some sulfonamides have also applications as diagnostic tools, in PET and MRI. Future prospects for drug design applications for inhibitors of these ubiquitous enzymes will also be discussed.
REFERENCE COUNT: 152 THERE ARE 152 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Carbonic anhydrase inhibitors

AB A review with 151 refs. CAs (EC 4.2.1.1) are wide-spread zinc enzymes, present in mammals in at least 14 different isoforms. Some of these isoenzymes are cytosolic (CA I, CA II, CA III, CA VII), others are membrane-bound (CA IV, CA IX, CA XII and CA XIV), CA V is mitochondrial and CA VI is secreted in the saliva. Three acatalytic forms are also known (CARP VIII, CARP X and CARP XI). Several important physiol. and physio-pathol. functions are played by many CA isoenzymes, which are strongly inhibited by aromatic and heterocyclic sulfonamides. The catalytic and inhibition mechanisms of these enzymes are understood in great detail, and this greatly helped the design of potent inhibitors, some of which possess important clin. applications. The use of such enzyme inhibitors as antiglaucoma drugs will be discussed in detail, together with the recent developments that led to isoenzyme-specific and organ-selective inhibitors. A recent discovery is connected with the involvement of CAs and their sulfonamide inhibitors in cancer: several potent sulfonamide inhibitors inhibited the growth of a multitude of tumor cells in vitro and in vivo, constituting thus interesting leads for developing novel antitumor therapies. Furthermore, some other classes of compds. that interact with CAs have recently been discovered, some of which possess modified sulfonamide or hydroxamate moieties. Some sulfonamides have also applications as diagnostic tools, in PET and MRI. Future prospects for drug design applications for inhibitors of these ubiquitous enzymes will also be discussed.

ST review carbonic anhydrase inhibitor antiglaucoma antitumor therapy

IT Antiglaucoma agents
Antitumor agents
Drug design

(carbonic anhydrase inhibitors)
IT 9001-03-0, Carbonic anhydrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(carbonic anhydrase inhibitors)

L11 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:881452 CAPLUS
DOCUMENT NUMBER: 123:296614
TITLE: Pretargeting methods and compounds with reduced immunogenicity of targeting moiety-anti-ligand conjugates or other components employed in diagnostic and therapeutic pretargeting protocols
INVENTOR(S): Graves, Scott S.; Bjorn, Michael J.; Reno, John M.; Axworthy, Donald B.; Fritzberg, Alan R.; Theodore, Louis J.
PATENT ASSIGNEE(S): Neorx Corp., USA
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9515770	A1	19950615	WO 1994-US14223	19941209
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1993-164302 A	19931209

AB Methods, compds., compns., and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods and agents are provided for reducing the immunogenicity of targeting moiety-anti-ligand conjugates or other components employed in diagnostic and therapeutic pretargeting protocols. Preparation of various conjugates for use in the invention is included. Examples include e.g. in vivo anal. of a radiolabeled chelate-biotin conjugate administered after antibody pretargeting, clearing agent evaluation, two- and three-step pretargeting methodol., administration of a monoclonal antibody (MAb)-streptavidin conjugate in humans, and immunosuppression of MAb-containing conjugates.
IT Neoplasm inhibitors
(conjugates with biotin; therapeutic and diagnostic pretargeting methods and compds., and conjugate preparation and evaluation)
IT Intestine, neoplasm
(colon, therapeutic and diagnostic pretargeting methods and compds., and conjugate preparation and evaluation)
IT Neoplasm inhibitors
(lung small-cell carcinoma, therapeutic and diagnostic pretargeting methods and compds., and conjugate preparation and evaluation)
IT Lung, neoplasm
(small-cell carcinoma, therapeutic and diagnostic pretargeting methods and compds., and conjugate preparation and evaluation)
IT Lung, neoplasm
(small-cell carcinoma, inhibitors, therapeutic and diagnostic pretargeting methods and compds., and conjugate preparation and evaluation)
IT 50-18-0, Cyclophosphamide 52-53-9, Verapamil 58-85-5D, Biotin, conjugates with therapeutic and linker 59-05-2, Methotrexate 59-23-4D, Galactose, conjugates with albumin and biotin 59-66-5, Acetazolamide 114-07-8, Erythromycin 364-62-5, Metoclopramide 446-86-6, Azathioprine 4759-48-2, Isotretinoin 9013-20-1D, Streptavidin, targeting moiety conjugates 10043-49-9D, Gold-198, biotin conjugates, biological studies 10043-66-0D, Iodine-131, biotin conjugates, biological studies 10098-91-6D, Yttrium-90, biotin conjugates, biological studies 14265-75-9D, Lutetium-177, biotin

conjugates, biological studies 14378-26-8D, Rhenium-188, biotin conjugates, biological studies 14913-49-6D, Bismuth-212, biotin conjugates, biological studies 14913-89-4D, biotin conjugates, biological studies 14998-63-1D, Rhenium-186, biotin conjugates, biological studies 15092-94-1D, Lead-212, biotin conjugates, biological studies 15715-08-9D, Iodine-123, biotin conjugates, biological studies 15750-15-9D, Indium-111, biotin conjugates, biological studies 15755-39-2D, Astatine-211, biotin conjugates, biological studies 15757-86-5D, Copper-67, biotin conjugates, biological studies 15766-00-4D, Samarium-153, biotin conjugates, biological studies 24280-93-1, Mycophenolic acid 25322-68-3D, streptavidin derivs. 42399-41-7, Diltiazem 51632-96-3D, Europium-169, biotin conjugates, biological studies 53123-88-9, Rapamycin 55985-32-5, Nicardipine 59865-13-3, Cyclosporin A 65277-42-1, Ketoconazole 86386-73-4, Fluconazole 89149-10-0, Deoxyspergualin 104987-11-3, FK506
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic and diagnostic pretargeting methods and compds., and conjugate preparation and evaluation)

L11 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:100166 CAPLUS
DOCUMENT NUMBER: 116:100166
TITLE: Method for increasing blood-brain barrier permeability by intravenous coadministration of bradykinin agonist
INVENTOR(S): Malfroy-Camine, Bernard; Smart, Janet L.
PATENT ASSIGNEE(S): Alkermes, Inc., USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9116355	A1	19911031	WO 1991-US2772	19910423
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, PL, RO, SD, SE, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
US 5112596	A	19920512	US 1990-512913	19900423
AU 9178606	A	19911111	AU 1991-78606	19910423
AU 650020	B2	19940609		
EP 528891	A1	19930303	EP 1991-909190	19910423
EP 528891	B1	20000705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05506859	T	19931007	JP 1991-509000	19910423
AT 194289	T	20000715	AT 1991-909190	19910423
ES 2147722	T3	20001001	ES 1991-909190	19910423
US 5506206	A	19960409	US 1993-121058	19930913
GR 3034351	T3	20001229	GR 2000-402039	20000906
PRIORITY APPLN. INFO.:			US 1990-512913 A2	19900423
			US 1991-690522 A3	19910423
			WO 1991-US2772 A	19910423

AB The permeability of the blood-brain barrier of a host to a (therapeutic or diagnostic) mol. is increased by i.v. coadministration of a bradykinin agonist of blood-brain permeability. [Hyp3, Thi5 4-Me-Tyr8Ψ(CH2NH)Arg9] bradykinin (A-7; Thi = thienylalanine; preparation given) increased the brain uptake of loperamide, domperidone, 3H-AZT, 99mTc-DISIDA, and others. Rats with brain tumor implants survived longer when treated with cisplatin coadministered with A-7.
AB The permeability of the blood-brain barrier of a host to a (therapeutic or diagnostic) mol. is increased by i.v. coadministration of a bradykinin agonist of blood-brain permeability. [Hyp3, Thi5

4-Me-Tyr8Ψ(CH2NH)Arg9] bradykinin (A-7; Thi = thienylalanine; preparation given) increased the brain uptake of loperamide, domperidone, 3H-AZT, 99mTc-DISIDA, and others. Rats with brain tumor implants survived longer when treated with cisplatin coadministered with A-7.

IT Neoplasm inhibitors
(cisplatin as, bradykinin agonist increasing blood-brain barrier permeability in relation to)

IT Brain, neoplasm
(inhibitors, cisplatin as, bradykinin agonist increasing blood-brain barrier permeability in relation to)

IT 57-50-1, Sucrose, biological studies 9001-03-0 9001-99-4 9040-95-3, 3H-Inulin 902457-23-2
RL: BIOL (Biological study)
(blood-brain barrier permeability to, bradykinin agonist effect on, mol. weight in relation to)

IT 62571-86-2, Captopril
RL: BIOL (Biological study)
(bradykinin degradation inhibition with, blood-brain barrier permeability to cisplatin in relation to)

amplification in response to a ligand, the cells containing a marker of cell amplification, with a test substance which is a potential agonist or antagonist of the receptor, and (b) after a period of time sufficient to permit cell amplification, determining the presence or absence of amplification of cells containing the marker relative to cells not containing the marker. Thus, 3T3 cells were transfected with DNA for the trk A receptor, stimulation of which activates tyrosine phosphorylation, and with DNA for β-galactosidase. Incubation of the cells with NGF, an agonist for the trk receptor, dose-dependently induced growth of the cells over the range 10-12-10-9M, as indicated by β-galactosidase activity.

L11 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:100166 CAPLUS
DOCUMENT NUMBER: 116:100166
TITLE: Method for increasing blood-brain barrier permeability by intravenous coadministration of bradykinin agonist
INVENTOR(S): Malfroy-Camine, Bernard; Smart, Janet L.
PATENT ASSIGNEE(S): Alkermes, Inc., USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9116355	A1	19911031	WO 1991-US2772	19910423
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, PL, RO, SD, SE, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
US 5112596	A	19920512	US 1990-512913	19900423
AU 9178606	A	19911111	AU 1991-78606	19910423
AU 650020	B2	19940609		
EP 528891	A1	19930303	EP 1991-909190	19910423
EP 528891	B1	20000705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05506859	T	19931007	JP 1991-509000	19910423
AT 194289	T	20000715	AT 1991-909190	19910423
ES 2147722	T3	20001001	ES 1991-909190	19910423
US 5506206	A	19960409	US 1993-121058	19930913
GR 3034351	T3	20001229	GR 2000-402039	20000906
PRIORITY APPLN. INFO.:			US 1990-512913 A2	19900423
			US 1991-690522 A3	19910423
			WO 1991-US2772 A	19910423

AB The permeability of the blood-brain barrier of a host to a (therapeutic or diagnostic) mol. is increased by i.v. coadministration of a bradykinin agonist of blood-brain permeability. [Hyp3, Thi5 4-Me-Tyr8Ψ(CH2NH)Arg9] bradykinin (A-7; Thi = thienylalanine; preparation given) increased the brain uptake of loperamide, domperidone, 3H-AZT, 99mTc-DISIDA, and others. Rats with brain tumor implants survived longer when treated with cisplatin coadministered with A-7.

=> d ibib ab kwic 3, 7, 9

L11 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:361504 CAPLUS
DOCUMENT NUMBER: 135:146678
TITLE: Carbonic anhydrase inhibitors
AUTHOR(S): Supuran, Claudiu T.; Scozzafava, Andrea
CORPORATE SOURCE: Universita degli Studi, Laboratorio di Chimica